

Reference Searched my database for clinical trials and cannabis

1. Sarris, J., McIntyre, E. & Camfield, D. A. Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. *CNS Drugs* **27**, 301-319 (2013).
2. Naftali, T. et al. Cannabis Induces a Clinical Response in Patients with Crohn's Disease: a Prospective Placebo-Controlled Study. *Clin Gastroenterol Hepatol* (2013).
3. Lee, M. C. et al. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. *Pain* **154**, 124-134 (2013).
4. Schicho, R. & Storr, M. Topical and Systemic Cannabidiol Improves Trinitrobenzene Sulfonic Acid Colitis in Mice. *Pharmacology* **89**, 149-155 (2012).
5. Grotenhermen, F. & Muller-Vahl, K. The therapeutic potential of cannabis and cannabinoids. *Dtsch Arztebl Int* **109**, 495-501 (2012).
6. Zamberletti, E., Rubino, T. & Parolaro, D. The endocannabinoid system and schizophrenia: integration of evidence. *Curr Pharm Des* (2012).
7. Vandrey, R. et al. The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. *Drug Alcohol Depend* (2012).
8. Stern, C. A., Gazarini, L., Takahashi, R. N., Guimaraes, F. S. & Bertoglio, L. J. On Disruption of Fear Memory by Reconsolidation Blockade: Evidence from Cannabidiol Treatment. *Neuropsychopharmacology* (2012).
9. Bosker, W. M. et al. Medicinal Delta(9) -tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. *Addiction* **107**, 1837-1844 (2012).
10. Eichler, M. et al. Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. *Planta Med* **78**, 686-691 (2012).
11. Wade, D. Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough? *Expert Rev Neurother* **12**, 9-14 (2012).
12. Katsidoni, V., Anagnostou, I. & Panagis, G. Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT(1A) receptors in the dorsal raphe nucleus. *Addict Biol* (2012).
13. Wright, S., Duncombe, P. & Altman, D. G. Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex(R)) in people with multiple sclerosis: a new approach. *Trials* **13**, 189 (2012).
14. Levin, R. et al. Antipsychotic Profile of Cannabidiol and Rimonabant in an Animal Model of Emotional Context Processing in Schizophrenia. *Curr Pharm Des* (2012).
15. Karschner, E. L. et al. Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration. *Clin Pharmacol Ther* (2011).
16. Morgan, C. J. et al. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. *Psychol Med* **1-10** (2011).
17. Weinstein, A. M. & Gorelick, D. A. Pharmacological Treatment of Cannabis Dependence. *Curr Pharm Des* (2011).
18. Klumpers, L. E. et al. Novel Delta(9) -tetrahydrocannabinol formulation

- Namisol(R) has beneficial pharmacokinetics and promising pharmacodynamic effects. *Br J Clin Pharmacol* (2011).
19. Sagredo, O. et al. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. *J Neurosci Res* (2011).
 20. Lahat, A., Lang, A. & Ben-Horin, S. Impact of Cannabis Treatment on the Quality of Life, Weight and Clinical Disease Activity in Inflammatory Bowel Disease Patients: A Pilot Prospective Study. *Digestion* **85**, 1-8 (2011).
 21. Kelly, D. L. et al. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. *J Clin Psychopharmacol* **31**, 86-91 (2011).
 22. Beck, O., Sandqvist, S., Dubbelboer, I. & Franck, J. Detection of delta(9)-tetrahydrocannabinol in exhaled breath collected from cannabis users. *J Anal Toxicol* **35**, 541-544 (2011).
 23. Kowal, M. A., Colzato, L. S. & Hommel, B. Decreased spontaneous eye blink rates in chronic cannabis users: evidence for striatal cannabinoid-dopamine interactions. *PLoS One* **6**, e26662 (2011).
 24. Schubart, C. D. et al. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. *Schizophr Res* (2011).
 25. Buchowski, M. S. et al. Aerobic exercise training reduces cannabis craving and use in non-treatment seeking cannabis-dependent adults. *PLoS One* **6**, e17465 (2011).
 26. Steentoft, A., Simonsen, K. W. & Linnet, K. The frequency of drugs among danish drivers before and after the introduction of fixed concentration limits. *Traffic Inj Prev* **11**, 329-333 (2010).
 27. Porath-Waller, A. J. & Beirness, D. J. Simplifying the process for identifying drug combinations by drug recognition experts. *Traffic Inj Prev* **11**, 453-459 (2010).
 28. Sharma, P., Bharath, M. M. & Murthy, P. Qualitative high performance thin layer chromatography (HPTLC) analysis of cannabinoids in urine samples of Cannabis abusers. *Indian J Med Res* **132**, 201-208 (2010).
 29. Duran, M. et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. *Br J Clin Pharmacol* **70**, 656-663 (2010).
 30. Brenneisen, R., Meyer, P., Chtioui, H., Saugy, M. & Kamber, M. Plasma and urine profiles of Delta(9)-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-Delta (9)-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes. *Anal Bioanal Chem* (2010).
 31. Swartz, R. Medical marijuana users in substance abuse treatment. *Harm Reduct J* **7**, 3 (2010).
 32. Bramness, J. G., Khiabani, H. Z. & Morland, J. Impairment due to cannabis and ethanol: clinical signs and additive effects. *Addiction* (2010).
 33. Morgan, C. J., Schafer, G., Freeman, T. P. & Curran, H. V. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. *Br J Psychiatry* **197**, 285-290 (2010).
 34. Liem-Moolenaar, M. et al. Central nervous system effects of haloperidol on THC in healthy male volunteers. *J Psychopharmacol* (2010).
 35. Burns, J. K., Jhazbhay, K. & Emsley, R. Cannabis use predicts shorter duration of

- untreated psychosis and lower levels of negative symptoms in first-episode psychosis: a South African study. *Afr J Psychiatry (Johannesbg)* **13**, 395-399 (2010).
36. Cornelius, J. R., Aizenstein, H. J. & Hariri, A. R. Amygdala reactivity is inversely related to level of cannabis use in individuals with comorbid cannabis dependence and major depression. *Addict Behav* (2010).
 37. Cozzolino, R., Cali, G., Bifulco, M. & Laccetti, P. A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis. *Invest New Drugs* **28**, 115-123 (2010).
 38. Lakhan, S. E. & Rowland, M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. *BMC Neurol* **9**, 59 (2009).
 39. Koskinen, J., Lohonen, J., Koponen, H., Isohanni, M. & Miettunen, J. Rate of Cannabis Use Disorders in Clinical Samples of Patients With Schizophrenia: A Meta-analysis. *Schizophr Bull* (2009).
 40. Gerra, G. et al. Pharmacology and Toxicology of Cannabis Derivatives and Endocannabinoid Agonists. *Recent Pat CNS Drug Discov* (2009).
 41. Piechatek, M. et al. Is moderate substance use associated with altered executive functioning in a population-based sample of young adults? *Hum Psychopharmacol* **24**, 650-665 (2009).
 42. Huang, P., Liu-Chen, L. Y., Unterwald, E. M. & Cowan, A. Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice. *Neurosci Lett* (2009).
 43. Schulz-Katterbach, M., Imfeld, T. & Imfeld, C. Cannabis and caries--does regular cannabis use increase the risk of caries in cigarette smokers? *Schweiz Monatsschr Zahnmed* **119**, 576-583 (2009).
 44. Stokes, P. R., Mehta, M. A., Curran, H. V., Breen, G. & Grasby, P. M. Can recreational doses of THC produce significant dopamine release in the human striatum? *Neuroimage* (2009).
 45. Cozzolino, R., Cali, G., Bifulco, M. & Laccetti, P. A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis. *Invest New Drugs* (2009).
 46. Almeida, P. P., Novaes, M. A., Bressan, R. A. & Lacerda, A. L. [Review: executive functioning and cannabis use]. *Rev Bras Psiquiatr* **30**, 69-76 (2008).
 47. Hosking, R. D. & Zajicek, J. P. Therapeutic potential of cannabis in pain medicine. *Br J Anaesth* (2008).
 48. Bolla, K. I. et al. Sleep disturbance in heavy marijuana users. *Sleep* **31**, 901-908 (2008).
 49. Grauwiler, S. B., Drewe, J. & Scholer, A. Sensitivity and Specificity of Urinary Cannabinoid Detection With Two Immunoassays After Controlled Oral Administration of Cannabinoids to Humans. *Ther Drug Monit* (2008).
 50. Kraft, B. et al. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. *Anesthesiology* **109**, 101-110 (2008).
 51. Trezza, V. et al. Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the emotional reactivity of the offspring: a longitudinal behavioral study in Wistar rats. *Psychopharmacology (Berl)* (2008).

52. Richardson, D. et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteo- and rheumatoid arthritis. *Arthritis Res Ther* **10**, R43 (2008).
53. Hall, W. & Degenhardt, L. Cannabis Use and the Risk of Developing a Psychotic Disorder. *World Psychiatry* **7**, 68-71 (2008).
54. Tirado, C. F., Goldman, M., Lynch, K., Kampman, K. M. & O'Brien, C. P. Atomoxetine for treatment of marijuana dependence: A report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. *Drug Alcohol Depend* (2008).
55. Mariani, J. J. et al. Antisocial behavioral syndromes in cocaine and cannabis dependence. *Am J Drug Alcohol Abuse* **34**, 405-414 (2008).
56. Appendino, G. et al. Antibacterial Cannabinoids from Cannabis sativa: A Structure-Activity Study. *J Nat Prod* (2008).
57. Appendino, G. et al. Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. *J Nat Prod* **71**, 1427-1430 (2008).
58. Wilsey, B. et al. A Randomized, Placebo-Controlled, Crossover Trial of Cannabis Cigarettes in Neuropathic Pain. *J Pain* (2008).
59. Vaz Carneiro, S. & Borrego, M. [Psychosis and substance abuse]. *Acta Med Port* **20**, 413-422 (2007).
60. Abrams, D. I. et al. Vaporization as a Smokeless Cannabis Delivery System: A Pilot Study. *Clin Pharmacol Ther* (2007).
61. Harvey, M. A., Sellman, J. D., Porter, R. J. & Frampton, C. M. The relationship between non-acute adolescent cannabis use and cognition. *Drug Alcohol Rev* **26**, 309-319 (2007).
62. Huestis, M. A. et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. *Psychopharmacology (Berl)* (2007).
63. Rehman, I. U. & Farooq, S. Schizophrenia and comorbid self reported cannabis abuse: impact on course, functioning and services use. *J Pak Med Assoc* **57**, 60-64 (2007).
64. Rehman, I. U. & Farooq, S. Cannabis abuse in patients with schizophrenia: pattern and effects on symptomatology. *J Coll Physicians Surg Pak* **17**, 158-161 (2007).
65. Bambico, F. R., Katz, N., Debonnel, G. & Gobbi, G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. *J Neurosci* **27**, 11700-11711 (2007).
66. Velasco, G. et al. Cannabinoids and gliomas. *Mol Neurobiol* **36**, 60-67 (2007).
67. Muccioli, G. G. Blocking the Cannabinoid Receptors: Drug Candidates and Therapeutic Promises. *Chem Biodivers* **4**, 1805-1827 (2007).
68. Vandrey, R. G., Budney, A. J., Hughes, J. R. & Liguori, A. A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. *Drug Alcohol Depend* (2007).
69. Giroud, C. et al. [Effects of oral cannabis and dronabinol on driving capacity.]. *Ann Pharm Fr* **64**, 161-172 (2006).
70. Vidinsky, B., Gal, P. & Mojzis, J. [Different views on the association between cannabinoids and cancer]. *Cas Lek Cesk* **145**, 453-7; discussion 458 (2006).
71. Freeman, R. M. et al. The effect of cannabis on urge incontinence in patients with

- multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). *Int Urogynecol J Pelvic Floor Dysfunct* (2006).
72. Manzanares, J., Julian, M. & Carrascosa, A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. *Curr Neuropharmacol* **4**, 239-257 (2006).
 73. Blake, D. R., Robson, P., Ho, M., Jubb, R. W. & McCabe, C. S. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. *Rheumatology (Oxford)* **45**, 50-52 (2006).
 74. Ware, M. A., Ducruet, T. & Robinson, A. R. Evaluation of herbal cannabis characteristics by medical users: a randomized trial. *Harm Reduct J* **3**, 32 (2006).
 75. Hazekamp, A., Ruhaak, R., Zuurman, L., van Gerven, J. & Verpoorte, R. Evaluation of a vaporizing device (Volcano(R)) for the pulmonary administration of tetrahydrocannabinol. *J Pharm Sci* **95**, 1308-1317 (2006).
 76. Khare, M., Taylor, A. H., Konje, J. C. & Bell, S. C. Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. *Mol Hum Reprod* **12**, 321-333 (2006).
 77. Aharonovich, E. et al. Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence: effects on outcome. *Am J Drug Alcohol Abuse* **32**, 629-635 (2006).
 78. Strasser, F. et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. *J Clin Oncol* **24**, 3394-3400 (2006).
 79. Copersino, M. L. et al. Cannabis withdrawal among non-treatment-seeking adult cannabis users. *Am J Addict* **15**, 8-14 (2006).
 80. Konings, M. & Maharajh, H. D. Cannabis use and mood disorders: patterns of clinical presentations among adolescents in a developing country. *Int J Adolesc Med Health* **18**, 221-233 (2006).
 81. Ben Amar, M. Cannabinoids in medicine: A review of their therapeutic potential. *J Ethnopharmacol* **105**, 1-25 (2006).
 82. Klein, T. W. & Cabral, G. A. Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. *J Neuroimmune Pharmacol* **1**, 50-64 (2006).
 83. Burns, T. L. & Ineck, J. R. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. *Ann Pharmacother* **40**, 251-260 (2006).
 84. Russo, E. & Guy, G. W. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. *Med Hypotheses* **66**, 234-246 (2006).
 85. Holdcroft, A., Maze, M., Dore, C., Tebbs, S. & Thompson, S. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. *Anesthesiology* **104**, 1040-1046 (2006).
 86. Trebst, C. & Stangel, M. [Cannabinoids in multiple sclerosis -- therapeutically reasonable?]. *Fortschr Neurol Psychiatr* **73**, 463-469 (2005).
 87. Ware, M. A., Adams, H. & Guy, G. W. The medicinal use of cannabis in the UK:

- results of a nationwide survey. *Int J Clin Pract* **59**, 291-295 (2005).
88. Bortolato, M. et al. The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. *Psychopharmacology (Berl)* **177**, 264-271 (2005).
 89. Caspi, A. et al. Moderation of the Effect of Adolescent-onset Cannabis Use on Adult Psychosis By a Functional Polymorphism in the Catechol-o-methyltransferase Gene: Longitudinal Evidence of a Gene X Environment Interaction. *Biol Psychiatry* **57**, 1117-1127 (2005).
 90. Isaac, M., Isaac, M. & Holloway, F. Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care. *Hum Psychopharmacol* **20**, 207-210 (2005).
 91. Huestis, M. A., Barnes, A. & Smith, M. L. Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations. *Clin Chem* **51**, 2289-2295 (2005).
 92. Callaway, J. et al. Efficacy of dietary hempseed oil in patients with atopic dermatitis. *J Dermatolog Treat* **16**, 87-94 (2005).
 93. Katona, S., Kaminski, E., Sanders, H. & Zajicek, J. Cannabinoid influence on cytokine profile in multiple sclerosis. *Clin Exp Immunol* **140**, 580-585 (2005).
 94. Vandrey, R. G., Budney, A. J., Moore, B. A. & Hughes, J. R. A cross-study comparison of cannabis and tobacco withdrawal. *Am J Addict* **14**, 54-63 (2005).
 95. Gustafson, R. A. et al. Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration. *J Anal Toxicol* **28**, 160-167 (2004).
 96. D'Andrea G, T. S., Leon A, Fortin D, Perini F, Granella F, Bussone G. PATHOPHYSIOLOGY, BASIC SCIENCE, AND CLINICAL STUDIES. *Headache* **44**, 1063-1065 (2004).
 97. Costa, B. et al. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. *Naunyn Schmiedebergs Arch Pharmacol* **369**, 294-299 (2004).
 98. Russo, E. B. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? *Neuro Endocrinol Lett* **25**, 31-39 (2004).
 99. Russo, E. B., Merzouki, A., Mesa, J. M., Frey, K. A. & Bach, P. J. Cannabis improves night vision: a case study of dark adaptometry and scotopic sensitivity in kif smokers of the Rif mountains of northern Morocco. *J Ethnopharmacol* **93**, 99-104 (2004).
 100. Carroll, C. B. et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. *Neurology* **63**, 1245-1250 (2004).
 101. Ellgren, M., Hurd, Y. L. & Franck, J. Amphetamine effects on dopamine levels and behavior following cannabinoid exposure during adolescence. *Eur J Pharmacol* **497**, 205-213 (2004).
 102. Gustafson, R. A. et al. Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans. *Clin Chem* **49**, 1114-1124 (2003).
 103. Muller-Vahl, K. R. et al. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. *Neuropsychopharmacology* **28**, 384-388 (2003).

104. Budney, A. J., Moore, B. A., Vandrey, R. G. & Hughes, J. R. The time course and significance of cannabis withdrawal. *J Abnorm Psychol* **112**, 393-402 (2003).
105. Naef, M. et al. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. *Pain* **105**, 79-88 (2003).
106. Peters, F. T., Maurer, H. H. & Hellstern, P. Prevalence of illicit drug use in plasmapheresis donors. *Vox Sang* **84**, 91-95 (2003).
107. Grant, I., Gonzalez, R., Carey, C. L., Natarajan, L. & Wolfson, T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. *J Int Neuropsychol Soc* **9**, 679-689 (2003).
108. Marchese, G. et al. Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. *Br J Pharmacol* **140**, 520-526 (2003).
109. Muller-Vahl, K. R. et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. *J Clin Psychiatry* **64**, 459-465 (2003).
110. Ware, M. A., Doyle, C. R., Woods, R., Lynch, M. E. & Clark, A. J. Cannabis use for chronic non-cancer pain: results of a prospective survey. *Pain* **102**, 211-216 (2003).
111. Muller-Vahl, K. R. Cannabinoids reduce symptoms of Tourette's syndrome. *Expert Opin Pharmacother* **4**, 1717-1725 (2003).
112. Zajicek, J. et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. *Lancet* **362**, 1517-1526 (2003).
113. Clermont-Gnamien, S. et al. [The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain]. *Presse Med* **31**, 1840-1845 (2002).
114. Beaulieu, P. & Rice, A. S. [The pharmacology of cannabinoid derivatives: are there applications to treatment of pain?]. *Ann Fr Anesth Reanim* **21**, 493-508 (2002).
115. Muller-Vahl, K. R. et al. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. *Pharmacopsychiatry* **35**, 57-61 (2002).
116. Curran, H. V., Brignell, C., Fletcher, S., Middleton, P. & Henry, J. Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. *Psychopharmacology (Berl)* **164**, 61-70 (2002).
117. Ware, M. A., Gamsa, A., Persson, J. & Fitzcharles, M. A. Cannabis for chronic pain: case series and implications for clinicians. *Pain Res Manag* **7**, 95-99 (2002).
118. Porcella, A., Maxia, C., Gessa, G. L. & Pani, L. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. *Eur J Neurosci* **13**, 409-412 (2001).
119. Kalant, H. Medicinal use of cannabis: history and current status. *Pain Res Manag* **6**, 80-91 (2001).
120. ElSohly, M. A., deWit, H., Wachtel, S. R., Feng, S. & Murphy, T. P. Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. *J Anal Toxicol* **25**, 565-571 (2001).
121. Campbell, F. A. et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. *BMJ* **323**, 13-16 (2001).

122. Watson, S. J., Benson, J. A. J. & Joy, J. E. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. *Arch Gen Psychiatry* **57**, 547-552 (2000).
123. Fishbain, D. A., Cutler, R. B., Rosomoff, H. L. & Rosomoff, R. S. Validity of self-reported drug use in chronic pain patients. *Clin J Pain* **15**, 184-191 (1999).
124. Fraser, A. D. & Worth, D. Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol: a delta9-THCCOOH to creatinine ratio study. *J Anal Toxicol* **23**, 531-534 (1999).
125. Mitka, M. Therapeutic marijuana use supported while thorough proposed study done. *JAMA* **281**, 1473-1474 (1999).
126. Sherwood, R. A., Keating, J., Kavvadia, V., Greenough, A. & Peters, T. J. Substance misuse in early pregnancy and relationship to fetal outcome. *Eur J Pediatr* **158**, 488-492 (1999).
127. McPartland, J. M. & Pruitt, P. L. Side effects of pharmaceuticals not elicited by comparable herbal medicines: the case of tetrahydrocannabinol and marijuana. *Altern Ther Health Med* **5**, 57-62 (1999).
128. Perkonig, A. et al. Patterns of cannabis use, abuse and dependence over time: incidence, progression and stability in a sample of 1228 adolescents. *Addiction* **94**, 1663-1678 (1999).
129. Rosenthal, M. S. & Kleber, H. D. Making sense of medical marijuana. *Proc Assoc Am Physicians* **111**, 159-165 (1999).
130. Gorriti, M. A., Rodriguez de Fonseca, F., Navarro, M. & Palomo, T. Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. *Eur J Pharmacol* **365**, 133-142 (1999).
131. Schneider, U., Leweke, F. M., Mueller-Vahl, K. R. & Emrich, H. M. Cannabinoid/anandamide system and schizophrenia: is there evidence for association? *Pharmacopsychiatry* **31 Suppl 2**, 110-113 (1998).
132. Taylor, H. G. Analysis of the medical use of marijuana and its societal implications. *J Am Pharm Assoc (Wash)* **38**, 220-227 (1998).
133. Holdcroft, A. et al. Pain relief with oral cannabinoids in familial Mediterranean fever. *Anaesthesia* **52**, 483-486 (1997).
134. Wiesbeck, G. A. et al. An evaluation of the history of a marijuana withdrawal syndrome in a large population. *Addiction* **91**, 1469-1478 (1996).
135. Winterer, G., Schmidt, L. G., Frick, K. & Ulrich, G. ["Neuroadaptation" in long-term cannabis abuse. A clinical and electroencephalographic case study]. *Nervenarzt* **65**, 635-637 (1994).
136. Schwartz, R. H. & Beveridge, R. A. Marijuana as an antiemetic drug: how useful is it today? Opinions from clinical oncologists. *J Addict Dis* **13**, 53-65 (1994).
137. Martinez, F. et al. Cocaine metabolite (benzoylecgonine) in hair and urine of drug users. *J Anal Toxicol* **17**, 138-142 (1993).
138. Huestis, M. A., Henningfield, J. E. & Cone, E. J. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH). *J Anal Toxicol* **16**, 283-290 (1992).
139. Plasse, T. F. Clinical use of dronabinol. *J Clin Oncol* **9**, 2079-2080 (1991).
140. Imade, A. G. & Ebie, J. C. A retrospective study of symptom patterns of cannabis-

- induced psychosis. *Acta Psychiatr Scand* **83**, 134-136 (1991).
141. Solomons, K., Neppe, V. M. & Kuyl, J. M. Toxic cannabis psychosis is a valid entity. *S Afr Med J* **78**, 476-481 (1990).
 142. Busto, U., Bendayan, R. & Sellers, E. M. Clinical pharmacokinetics of non-opiate abused drugs. *Clin Pharmacokinet* **16**, 1-26 (1989).
 143. Sethi, B. B. et al. Antianxiety effect of cannabis: involvement of central benzodiazepine receptors. *Biol Psychiatry* **21**, 3-10 (1986).
 144. Frederick, D. L., Green, J. & Fowler, M. W. Comparison of six cannabinoid metabolite assays. *J Anal Toxicol* **9**, 116-120 (1985).
 145. Willson, N. J., Kogan, M. J., Pierson, D. J. & Newman, E. Confirmation of EMIT cannabinoid assay results by bonded phase adsorption with thin layer chromatography. *J Toxicol Clin Toxicol* **20**, 465-473 (1983).
 146. Ungerleider, J. T. et al. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. *Cancer* **50**, 636-645 (1982).
 147. Perez-Reyes, M., Owens, S. M. & Di Guiseppi, S. The clinical pharmacology and dynamics of marijuana cigarette smoking. *J Clin Pharmacol* **21**, 201S-207S (1981).
 148. Dow, G. J. & Meyers, F. H. The California program for the investigational use of THC and marijuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapy. *J Clin Pharmacol* **21**, 128S-132S (1981).
 149. Lindgren, J. E., Ohlsson, A., Agurell, S., Hollister, L. & Gillespie, H. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. *Psychopharmacology (Berl)* **74**, 208-212 (1981).
 150. Parker, E. S. et al. Retrograde enhancement of human memory with alcohol. *Psychopharmacology (Berl)* **69**, 219-222 (1980).
 151. Tashkin, D. P., Calvarese, B. M., Simmons, M. S. & Shapiro, B. J. Respiratory status of seventy-four habitual marijuana smokers. *Chest* **78**, 699-706 (1980).
 152. Sell, S. H. Medical applications and use of marijuana--a study by the Tennessee Department of Public Health. *J Tenn Med Assoc* **73**, 187-189 (1980).
 153. Colls, B. M. Cannabis and cancer chemotherapy. *Lancet* **1**, 1187-1188 (1980).
 154. Tashkin, D. P., Levisman, J. A., Abbasi, A. S., Shapiro, B. J. & Ellis, N. M. Short-term effects of smoked marijuana on left ventricular function in man. *Chest* **72**, 20-26 (1977).
 155. Roth, W. T., Tinklenberg, J. R. & Kopell, B. S. Ethanol and marijuana effects on event-related potentials in a memory retrieval paradigm. *Electroencephalogr Clin Neurophysiol* **42**, 381-388 (1977).
 156. Melges, F. T. Tracking difficulties and paranoid ideation during hashish and alcohol intoxication. *Am J Psychiatry* **133**, 1024-1028 (1976).
 157. Chase, A. R., Kelley, P. R., Taunton-Rigby, A., Jones, R. T. & Harwood, T. Quantitation of cannabinoids in biological fluids by radioimmunoassay. *NIDA Res Monogr* **7**, 1-9 (1976).
 158. Dalton, W. S., Martz, R., Lemberger, L., Rodda, B. E. & Forney, R. B. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. *Clin Pharmacol Ther* **19**, 300-309 (1976).
 159. Evans, M. A., Martz, R., Rodda, B. E., Lemberger, L. & Forney, R. B. Effects of marijuana-dextroamphetamine combination. *Clin Pharmacol Ther* **20**, 350-358 (1976).

160. Razdan, R. K. et al. Drugs derived from cannabinoids. 2. Basic esters of nitrogen and carbocyclic analogs. *J Med Chem* **19**, 454-461 (1976).
161. Perez-Reyes, M. Clinical study of frequent marijuana use: adrenal cortical reserve metabolism of a contraceptive agent and development of tolerance. *Ann N Y Acad Sci* **282**, 173-179 (1976).
162. Jones, R. T., Benowitz, N. & Bachman, J. Clinical studies of cannabis tolerance and dependence. *Ann N Y Acad Sci* **282**, 221-239 (1976).
163. Gregg, J. M., Campbell, R. L., Levin, K. J., Ghia, J. & Elliott, R. A. Cardiovascular effects of cannabinol during oral surgery. *Anesth Analg* **55**, 203-213 (1976).
164. Dittrich, A., Bickel, P. & Zimmer, D. [Effects of (-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC) on tests of psychoticism. A study of Eysenck's drug postulate on the effects of hallucinogens in relation to psychoticism (author's transl)]. *Psychopharmacologia* **40**, 351-358 (1975).
165. Deniker, P., Ginestet, D., Etevenon, P. & Peron-magnan, P. [Comparison of clinical effects of delta-9-tetrahydrocannabinol with the classic effects of hashish]. *Encephale* **1**, 33-41 (1975).
166. Hollister, L. E. & Gillespie, H. Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol. *Clin Pharmacol Ther* **18**, 80-83 (1975).
167. Sallan, S. E., Zinberg, N. E. & Frei, E. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. *N Engl J Med* **293**, 795-797 (1975).
168. Adams, A. J., Brown, B., Flom, M. C., Jones, R. T. & Jampolsky, A. Alcohol and marijuana effects on static visual acuity. *Am J Optom Physiol Opt* **52**, 729-735 (1975).
169. Davies, B. H., Radcliffe, S., Seaton, A. & Graham, J. D. A trial of oral delta-1-(trans)-tetrahydrocannabinol in reversible airways obstruction. *Thorax* **30**, 80-85 (1975).
170. Carlini, E. A. [Pharmacology of marihuana]. *Arch Invest Med (Mex)* **5 SUPPL 1**, 151-160 (1974).
171. Deniker, P. et al. [Clinical pharmacology of delta-9-tetra-hydro-cannabinol in healthy volunteers with polygraphic control]. *Therapie* **29**, 185-200 (1974).
172. Harmon, J. W. & Aliapoulos, M. A. Marijuana-induced gynecomastia: clinical and laboratory experience. *Surg Forum* **25**, 423-425 (1974).
173. Dittrich, A., Battig, K. & von Zeppelin, I. Effects of (-)delta 9-trans-tetrahydrocannabinol (delta 9-THC) on memory, attention and subjective state. A double blind study. *Psychopharmacologia* **33**, 369-376 (1973).
174. Sidell, F. B. et al. Dimethylheptyl-delta 6a-10a-tetrahydrocannabinol: effects after parenteral administration to man. *Proc Soc Exp Biol Med* **142**, 867-873 (1973).
175. Perez-Reyes, M. et al. A comparison of the pharmacological activity of delta 9-tetrahydrocannabinol and its monohydroxylated metabolites in man. *Experientia* **29**, 1009-1010 (1973).
176. Perez-Reyes, M., Timmons, M. C., Lipton, M. A., Davis, K. H. & Wall, M. E. Intravenous injection in man of 9 -tetrahydrocannabinol and 11-OH- 9 -tetrahydrocannabinol. *Science* **177**, 633-635 (1972).
177. Pivik, R. T., Zarcone, V., Dement, W. C. & Hollister, L. E. Delta-9-tetrahydrocannabinol and synhexl: effects on human sleep patterns. *Clin Pharmacol*

- Ther* **13**, 426-435 (1972).
178. Hollister, L. E. Actions of various marihuana derivatives in man. *Pharmacol Rev* **23**, 349-357 (1971).
179. Jones, R. T. & Stone, G. C. Psychological studies of marijuana and alcohol in man. *Psychopharmacologia* **18**, 108-117 (1970).